Overview of Xatral LP

Quick Facts

Property	Description
Active Ingredient	Alfuzosin hydrochloride
Form	Prolonged-Release Tablet (XL formulation)
Pharmacological Class	Alpha-1 Adrenergic Antagonist (Alpha-blocker)
General Purpose	To support improved urine flow
Origin	Synthetic (quinazoline derivative)

The Identity and Pharmacological Class of Xatral LP

Xatral LP is a prescription-only medication formulated for oral use, primarily intended for the adult male population. Its active component is Alfuzosin, specifically used as Alfuzosin hydrochloride, a single-ingredient product recognized for its targeted efficacy. The medicine is classified within the pharmacological class of Alpha-1 Adrenergic Antagonists, commonly known as alpha-blockers. As a synthetic compound classified as a quinazoline derivative, Alfuzosin’s mechanism is clinically recognized for its ability to precisely modulate specific receptors in the urinary tract. The established therapeutic role of this classification is to directly address the constriction caused by muscle tension in this area.

Xatral LP: Prolonged-Release Form and General Purpose

The defining characteristic of Xatral LP is its dosage form: a prolonged-release tablet, often referred to as the XL formulation. This design is critical as it controls the rate at which Alfuzosin is delivered, specifically engineered for an extended duration of action over 24 hours. The sustained presence of Alfuzosin is paramount for achieving consistent relaxation of smooth muscle tissue. This therapeutic effect is focused on easing the muscular constriction around the bladder neck and prostate. By maintaining continuous muscle relaxation, the medication’s general purpose is to support and promote improved urine flow for individuals experiencing urinary restrictions. This prolonged-release approach provides for consistent symptomatic management.

Regulatory References

MedlinePlus

What side effects are possible with Xatral LP?

Possible Side Effects and Safety Information

The safety profile for Xatral LP (Alfuzosin prolonged-release) is based on official classifications documented in government regulatory sources, which categorize adverse reactions by frequency and affected organ system.

Frequency-Classified Reactions

Adverse reactions are organized based on their documented incidence:

Common (occurring in 1% to 10% of patients): Reactions include Dizziness, Headache, Asthenia (weakness), Nausea, and Postural Hypotension. These vascular and nervous system effects are often transient and may occur primarily at the beginning of treatment.
Uncommon (occurring in 0.1% to 1% of patients): Syncope (fainting), Tachycardia, Palpitations, Chest Pain, Diarrhoea, and Oedema (swelling) are documented in this category.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list serious reactions, which, while rare, are clinically significant. These include Priapism (a persistent, painful erection), Angioedema (swelling of the face, lips, or tongue), and Intraoperative Floppy Iris Syndrome (IFIS) observed during cataract surgery.

Safety-related restrictions define specific limitations on the use of this medicine. Xatral LP is contraindicated (should not be used) in patients with severe hepatic impairment or those concurrently taking other alpha-1 adrenergic antagonists or potent CYP3A4 inhibitors. Additionally, the prolonged-release tablet must be swallowed whole; altering the tablet is prohibited as it can lead to inappropriate drug release and heightened risk of adverse effects. Prior to initiating treatment, official labeling requires that prostate carcinoma must be ruled out.

Overdose and Emergency Response

Overdose Scope

Domain	Official Regulatory Statement
Documented Overdose Presentations	The principal clinical manifestation of overexposure is hypotension (low blood pressure) [2.3]. Other symptoms officially associated with overdose include dizziness, fainting, lightheadedness, blurred vision, and nausea [2.9].
Physiological Systems Affected (as stated in label)	The cardiovascular system is the principal system affected, requiring immediate support [2.3].
Dose-related or Exposure-related Factors	The overdose profile addresses conditions arising from excessive exposure or acute overdosage [2.3].
Population-specific Overdose Notes	The risk of developing hypotension and related adverse reactions may be greater in elderly patients [2.3].
Emergency-response statements (as written in official documents)	Management requires support of the cardiovascular system, including placing the patient in the supine position, and potential use of intravenous fluids and vasopressors [2.3]. Monitoring of renal function is a mandated supportive action [2.3].
When immediate medical help is required	Seek immediate medical attention by contacting a poison control centre or presenting to the nearest hospital emergency department [2.1].

Overdose Classifications (High-Level)

Classification	Official Regulatory Statement
Severity classification	The potential for severe hypotension leading to serious outcomes such as syncope and collapse classifies this as a scenario requiring immediate, acute medical intervention [2.3, 2.9].
Regulatory basis (EMA / FDA / etc.)	The basis for these instructions is derived from the FDA Prescribing Information and equivalent regulatory documents [2.3].
Overdose-context constraints	The official label states that no specific antidote is known, and dialysis may not be of benefit due to the drug's high protein binding [1.3, 2.4].

Resulting Overdose Structure

Official overdose statements:

The central documented manifestation of overdose is hypotension, accompanied by potential symptoms like dizziness, lightheadedness, and nausea [2.3, 2.9].
Immediate medical attention is required for any suspected overdose, with contact to a poison control centre or the nearest hospital emergency department mandated [2.1].
Management procedures described in regulatory sources emphasize cardiovascular system support, starting with placing the patient in the supine position [2.3].

Connection to the overall overdose profile:

Regulatory documents define the overdose profile of Xatral LP through the acute onset of hypotension due to its pharmacological classification, dictating that a resulting severe drop in blood pressure is the primary risk factor. These documents explicitly mandate specific actions for seeking emergency help and outline the required supportive treatment procedures to manage the cardiovascular effects.

Therapeutic Uses of Xatral LP

What Xatral LP Treats: Main Uses and Benefits

Xatral LP (Alfuzosin prolonged-release) is primarily used for the symptomatic treatment of Benign Prostatic Hyperplasia (BPH). The drug is relevant for easing symptoms related to the lower urinary tract. This medication may assist with managing multiple symptoms associated with BPH, including urinary hesitancy, frequency, urgency, and nocturia. The drug provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Easing Lower Urinary Tract Symptoms (LUTS)

This medication is commonly used to help with symptom clusters that interfere with daily comfort, known collectively as LUTS. Applied in clinical settings that involve acute or unstable symptom patterns, it is relevant for easing symptoms like difficulty starting the stream, a weak urine flow, and the sensation of incomplete bladder emptying.

“The primary goal of this symptomatic assistance is to support the patient during difficult episodes by easing distress.”

Reducing Irritative Urinary Discomfort

The drug is applicable within clinical settings where additional symptomatic support is needed to manage irritative symptoms that may become intense or disruptive. It helps address symptoms that create noticeable physiological strain, supporting the patient during difficult episodes and assisting with maintaining functional stability.

Quick Fact: Supportive management of Urinary Urgency

Xatral LP is often used during phases when irritative symptoms, such as the sudden, compelling need to urinate, become more noticeable.

Regulatory References

MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Xatral LP

Official regulatory documents strictly define the patient population for Xatral LP (Alfuzosin prolonged-release).

Eligibility Scope

Populations for Whom Use is Allowed (As Stated in Label):

Adult Male Patients: The established population for the BPH indication.
Older Adults (65 years): Use is generally permitted, though caution is advised, especially in those 75 years.

Populations for Whom Use is Contraindicated:

Patients with moderate or severe hepatic impairment (liver failure).
Patients with known hypersensitivity to alfuzosin or tablet components.
Patients with postural hypotension.
Patients concurrently using other alpha-1 receptor blocking agents or certain potent CYP3A4 inhibitors (e.g., ketoconazole).

Condition-Specific Eligibility Rules:

Children and Adolescents (Pediatric): The medicine is not indicated for use in this population.
Severe Renal Impairment: Use is generally not recommended or requires caution (creatinine clearance < 30 mL/min).
Prostatic Carcinoma must be ruled out prior to the start of treatment.
Pregnancy and Lactation: Not applicable, as the medicine is not indicated for women.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Xatral LP

Interaction scope

Feature	Official Statement
Medicinal product categories with documented interactions	Other Alpha-1 Receptor Blockers, Potent CYP3A4 Inhibitors, Antihypertensive Agents, Nitrates, PDE5 Inhibitors, General Anesthetics.
Specific interacting medicines (if explicitly listed)	Ketoconazole, Itraconazole, Ritonavir, Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir, Diltiazem.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction (Metabolism Inhibition): Clearance is reduced by CYP3A4 inhibitors, leading to increased plasma concentrations (AUC/Cmax). Pharmacodynamic Interaction (Additive Effect): Combination with other blood pressure-lowering agents increases the risk of symptomatic hypotension.
Timing-based interaction rules (if applicable)	Administration Timing (Food): Must be taken with food and with the same meal each day for consistent absorption. Surgical Timing: Withdrawal is recommended 24 hours before surgery involving general anesthetics.
Population-specific interaction notes (if applicable)	Hepatic Impairment (Moderate/Severe): The drug is contraindicated due to reduced clearance and increased blood levels. Elderly Patients: Risk of hypotension may be greater.

Interaction classifications (high-level)

Classification	Detail
Interaction severity classification (as defined in official documents)	Contraindicated Combinations: Other Alpha-1 Blockers, Potent CYP3A4 Inhibitors. Caution/Restriction Required: Antihypertensives, Nitrates, PDE5 Inhibitors, General Anesthetics, Moderate CYP3A4 Inhibitors.
Regulatory basis	FDA Prescribing Information and EMA/National SmPC documents.

Resulting interaction structure

Official interaction statements:

Alfuzosin is contraindicated with other alpha-1 receptor blockers due to the potential for severe postural hypotension.
Co-administration with potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) is contraindicated because these agents significantly increase Alfuzosin plasma concentrations.
The co-administration of Alfuzosin with PDE5 inhibitors or nitrates carries a regulatory warning due to the potential risk of symptomatic hypotension.
Combining with general anesthetics has a label restriction recommending withdrawal 24 hours prior to surgery.
The exposure to Alfuzosin is increased when combined with the moderate CYP3A4 inhibitor Diltiazem.

Connection to the overall interaction profile (2–4 sentences):

The official regulatory documents define the product’s interaction structure primarily through two domains: strict contraindications against substances that severely inhibit the CYP3A4 metabolic pathway and mandatory warnings about additive hypotensive effects with other vasodilatory or blood pressure-lowering agents. This structure requires specific patient management, including mandated timing rules related to both food intake and the administration of general anesthetics, as explicitly stated in the prescribing information.

Mechanism of Action

How Xatral LP Works

The mechanism of Xatral LP is anchored entirely in its pharmacological classification as a selective Alpha-1 Adrenergic Antagonist. Its active molecule, Alfuzosin, operates by targeting specific molecular receptors in the lower urinary tract to facilitate relaxation and increase the maximum urinary flow rate ( Q max).

Targeted Alpha-1 Adrenergic Receptor Antagonism

Alfuzosin acts as a competitive antagonist of the post-synaptic alpha-1 adrenergic receptors (alpha1-ARs) located in the prostate and bladder neck. By blocking the binding site of the natural mediator norepinephrine, the drug initiates a signaling cascade that suppresses smooth muscle contraction.

Modulation of Autonomic Smooth Muscle Tone

This antagonism leads directly to the relaxation of the smooth muscle tissue, effectively lowering urethral resistance and influencing the dynamic component of bladder outlet resistance. This mechanism results in the key physiological consequence of an increased maximum urinary flow rate ( Q max), with the sustained effect maintained by the drug's prolonged-release formulation. The mechanism targets only the functional muscle tone and is inherently constrained against the fixed component (physical tissue enlargement) of any obstruction.

Dosage and Administration Information

How Xatral LP is Used: Official Administration Guidelines

Xatral LP (Alfuzosin 10 mg prolonged-release tablet) is administered via the oral route and is distinguished by specific administration rules to ensure the integrity of its extended-release profile. Its use is primarily structured around a once-daily schedule, simplifying the treatment regimen for long-term management.

Dosing and Administration Essentials

Instruction	Detail
Route of Administration	Oral (swallowing the tablet).
Standard Daily Dose	10 mg once daily for Benign Prostatic Hyperplasia (BPH).
Meal Timing	Must be taken immediately after the same meal each day. Absorption is significantly lower when fasting.
Tablet Integrity	The tablet must be swallowed whole and must not be chewed, crushed, split, or ground.
Duration (AUR)	Used as adjunctive therapy for 3 to 4 days in Acute Urinary Retention (AUR) with catheterization.

Population Constraints and Missed Doses

Use of the 10 mg tablet is contraindicated in patients with moderate or severe hepatic impairment. For the pediatric population, the drug is not indicated, as efficacy has not been demonstrated. If a dose is missed, the instruction is to skip the missed dose if it is almost time for the next scheduled dose; a double dose must not be taken to compensate.

This structured approach to intake—including the timing with food and the requirement to swallow the tablet whole—is designed to maintain the drug’s correct usage profile for consistent 24-hour release.

Recent Clinical Evidence

Research evidence / Overview of studies for Xatral LP

Evidence for use in Benign Prostatic Hyperplasia (BPH) Symptoms

Research has explored whether Xatral LP is associated with changes in the common symptoms associated with a non-cancerous enlarged prostate. The main evidence comes from clinical studies where outcomes related to physical discomfort and daily functioning were monitored. These studies monitored groups of men over defined time intervals to see how their symptoms evolved. Data show patterns related to how patient-reported experiences evolved during the study period, helping contextualize the short-term changes observed in the study populations. However, research does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes. Follow-up durations were limited in many early trials, and comparative evidence, which examines how Xatral LP was studied alongside other interventions, may also be lacking or of varying quality.

Evidence for use in Acute Urinary Retention Requiring Catheterization

Research has explored whether Xatral LP was studied in conditions involving periods of heightened symptoms, specifically in men who experienced acute urinary retention (AUR) requiring the temporary use of a catheter. The evidence generally stems from specific research where short-term symptom changes and temporary physiological imbalance were monitored by studies. The available data show patterns related to outcomes that were monitored in these acute research scenarios. Regarding this use, the evidence is limited, and sample sizes were modest in some of the research. Long-term effects following study participation in this specific acute scenario are not fully established. Therefore, certainty remains low, and evidence remains limited in this context.

Long-term studies and follow-up

Research has been conducted exploring how symptoms change over time in study participants observed over an extended period. These studies monitor patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning over several years. Evidence contributes to understanding symptom patterns and whether the changes measured during the initial study period were observed in the follow-up data. However, long-term effects are not fully established for all men. The quality of the available long-term evidence may vary, meaning the certainty about outcomes far into the future remains lower than for short-term effects.

Frequently Asked Questions (FAQ)

Common questions about Xatral LP (FAQ)

Q: What is the difference between BPH and prostate cancer in the context of Xatral LP?

A: BPH (enlarged prostate) and prostate cancer can both lead to similar urinary issues. Regulatory documents indicate that prostate carcinoma (cancer) must be ruled out before starting treatment with Xatral LP. The medicine is indicated for BPH symptoms, and this check ensures that a serious underlying condition is not overlooked.

Q: What is orthostatic hypotension, and why is it a possible concern with Xatral LP?

A: Xatral LP may cause postural hypotension, which is a temporary drop in blood pressure that happens when a person quickly stands up. This can result in dizziness or lightheadedness, particularly when the treatment is first started. Official sources advise patients to be aware of this potential side effect.

Q: What are the known effects of Xatral LP on the elderly population?

A: Official warnings state that use in older adults, especially those aged 75 years and above, requires caution. Regulatory documents indicate that the risk of hypotension (low blood pressure) and related side effects may be greater in this population.

Q: What is the bioavailability of Xatral LP under different use conditions?

A: The regulatory requirements for Xatral LP emphasize that absorption is significantly better when taken with food. The amount of the drug absorbed into the bloodstream can be up to 50% lower if the tablet is taken on an empty stomach. This difference in absorption is why the medication is directed to be taken immediately after a meal.

Q: Can Xatral LP be used by patients who have mild liver impairment?

A: Official guidance states that Xatral LP is strictly contraindicated for patients with moderate or severe hepatic impairment (liver problems). Any degree of liver impairment is an important factor to discuss with a healthcare provider.

Q: What is Intraoperative Floppy Iris Syndrome (IFIS)?

A: Intraoperative Floppy Iris Syndrome (IFIS) is a condition that can occur during cataract surgery in patients who have taken, or are currently taking, an alpha-blocker like Xatral LP. This syndrome can increase the risk of complications during the procedure. Due to this risk, the patient's use of alpha-blockers should be disclosed to the ophthalmic surgeon before any eye surgery.

Q: Are there any common side effects that can affect sexual function with Xatral LP?

A: Official product literature does not indicate that Xatral LP has a detrimental effect on sexual function. However, the regulatory documents do list the rare and serious event of priapism, which is a persistent, painful erection.

Q: Does Xatral LP cause retrograde ejaculation like some other alpha-blockers?

A: While general ejaculatory dysfunction is noted as an uncommon side effect in official sources, retrograde ejaculation specifically is not listed as a known adverse event for Xatral LP. The overall regulatory statement for this class is that it has no detrimental effect on sexual function, aside from rare adverse events like priapism.

Q: Is a runny or stuffy nose considered a frequent side effect of the drug?

A: According to regulatory documents, rhinitis (a runny or stuffy nose) is an uncommon side effect. This means it has been reported in a small percentage of patients, specifically between 0.1% and 1% of those taking the medication.

Q: Can Xatral LP be associated with a change in liver enzyme levels?

A: Reports in official documents mention very rare instances of hepatocellular injury and cholestatic liver disease. Signs of liver problems, such as yellowing of the skin or eyes, are clinically important symptoms that should be reported to a healthcare provider.

Q: Does taking Xatral LP increase the risk of experiencing a stroke?

A: Official warnings note that signs of severe symptoms, such as sudden weakness or numbness, should be addressed immediately. This is a general safety precaution mentioned in the context of severe reactions, but regulatory documents do not indicate that the drug itself increases the risk of stroke.

Q: How long does it typically take to see the benefits of Xatral LP?

A: Xatral LP is formulated for prolonged release over 24 hours to provide consistent relief. Official studies show that the maximum concentration of the drug in the body, which relates to its full effect, is typically reached about eight hours after a dose. Sustained symptomatic management relies on daily use of the medication.

Q: Can the long-term use of Xatral LP change its overall effect?

A: Clinical studies have monitored the effects, safety, and efficacy of Xatral LP over extended periods. Official information confirms that continuous use has been evaluated in BPH patients for up to 12 months to assess sustained symptomatic management.

Q: Is it safe to stop taking Xatral LP suddenly?

A: Regulatory information states that suddenly stopping the use of Xatral LP is not recommended. Symptoms are typically better controlled by continuing to take the medication, even if they have improved. Treatment discontinuation is a topic for discussion with a healthcare provider.

Q: What is the reason for initial dosing recommendations sometimes including bedtime administration?

A: Official prescribing information often specifies that the daily dose is to be taken immediately after the evening meal. This timing is designed for two reasons: to optimize the drug's absorption, and to minimize the potential effects of initial dizziness or postural hypotension during the day.

Q: Can Xatral LP affect a patient's ability to drive or operate machinery?

A: Regulatory sources state that caution is required when driving or operating machinery while taking Xatral LP. This warning is due to the risks of postural hypotension, weakness, and dizzy sensations, especially when the treatment is first started.

Q: Is Xatral LP a non-sedating alpha-blocker?

A: While Xatral LP is not typically classified as a sedating drug, official adverse event lists indicate that both drowsiness and vertigo (a spinning dizzy feeling) are noted as uncommon side effects.

Q: Is it advised to limit or avoid alcohol consumption while taking Xatral LP?

A: Regulatory patient information warns that Xatral LP may increase the effects of alcohol. Due to this potential interaction, limiting or avoiding alcohol consumption is generally recommended.

Q: Does the consumption of grapefruit or grapefruit juice affect Xatral LP?

A: Official interaction warnings note that grapefruit juice may increase the concentration of alfuzosin in the blood. This could potentially increase the risk of experiencing side effects such as low blood pressure. Due to this potential, patients are generally informed to avoid consuming grapefruit or its juice.

Q: Can Xatral LP be used to treat hypertension (high blood pressure)?

A: Although Xatral LP belongs to a class of drugs (alpha-blockers) that can affect blood pressure, official regulatory documents state that it is not approved for the treatment of high blood pressure (hypertension). Its only indicated use is for managing the symptoms of BPH.

Q: Is Xatral LP considered an anticholinergic medication?

A: Xatral LP is primarily classified as a selective Alpha-1 Adrenergic Antagonist (alpha-blocker). The regulatory texts describing the drug's mechanism of action specify its effects on adrenergic receptors and do not indicate that it possesses anticholinergic properties.

Q: Where should I dispose of unused or expired Xatral LP?

A: Unused or expired tablets must be disposed of following local pharmaceutical waste regulations. Specific disposal options include drug take-back programs or following guidance for disposal in household waste, as flushing is generally not recommended.

Q: What does the 'LP' stand for in Xatral LP?

A: The 'LP' designation on Xatral LP stands for prolonged-release (or long-acting). This means the tablet is specially formulated to release the active ingredient, alfuzosin, slowly and continuously into the body over a period of 24 hours.

Q: Does Xatral LP affect the PSA test result?

A: Studies indicate that taking Xatral LP does not have a significant impact on the results of the Prostate-Specific Antigen (PSA) blood test. However, because this test is used to screen for prostate carcinoma, official labeling requires that cancer be ruled out before starting the medication.

Q: Does Xatral LP cause fluid retention or edema?

A: Regulatory documents list oedema (a medical term for fluid retention or swelling) as an uncommon adverse event associated with Xatral LP. This means it has been reported in a small percentage of patients.

Q: How soon before surgery should Xatral LP be stopped?

A: Official warnings recommend that Xatral LP be withdrawn (stopped) 24 hours prior to any surgery that involves the use of general anesthetics. This is a precautionary measure to manage potential drug interactions during the procedure.

How should Xatral LP be stored and disposed of?

The official storage and disposal requirements for Xatral LP (alfuzosin prolonged-release tablets) are strictly defined by regulatory documents to maintain drug stability and ensure safety.

Storage Conditions

Temperature: Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Excursions between 15 C and 30 C are permitted.
Protection: The medicine must be kept in its original container, which should be tightly closed, to protect it from light and excessive moisture.
Child Safety: Xatral LP must be stored in a safe location, out of the sight and reach of children.

Disposal

Unused or expired tablets must be disposed of in accordance with local pharmaceutical waste regulations.
Do not discard the medicine into household waste or flush it down the toilet unless specifically authorized by local health authorities.

Xatral LP